导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 8.68% | 802/4773 |
| 近一周 | -2.31% | 1763/5462 |
| 近一月 | -4.17% | 2270/5421 |
| 近一季 | -6.30% | 2038/5209 |
| 近半年 | -1.09% | 1477/4920 |
| 近一年 | 15.92% | 648/4366 |
| 近两年 | 82.40% | 777/2954 |
| 近三年 | 50.33% | 529/2253 |
| 成立以来 | 97.54% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.22% 1010/4961 |
22.07% 1140/5312 |
- - |
- - |
| 2025 | 33.95% 1088/4813 |
2.87% 1245/3635 |
2.31% 1660/4076 |
23.65% 1525/4524 |
2.93% 809/4813 |
| 2024 | 7.14% 1689/3463 |
-1.54% 1240/2808 |
-3.83% 1423/3014 |
13.96% 2068/3129 |
-0.72% 1503/3463 |
| 2023 | -8.71% 1050/2656 |
3.54% 1171/2280 |
-4.48% 1187/2385 |
-4.38% 1126/2515 |
-3.48% 702/2655 |
| 2022 | -15.91% 437/2207 |
-8.99% 305/1919 |
3.90% 1078/2016 |
-9.40% 276/2113 |
-1.84% 1745/2208 |
| 2021 | 22.27% 151/1822 |
2.61% 214/1255 |
12.19% 342/1330 |
7.48% 185/1466 |
-1.18% 1327/1822 |
| 2020 | 34.43% 438/1250 |
-6.71% 505/1028 |
18.39% 338/1067 |
16.62% 142/1164 |
4.37% 846/1184 |
| 2019 | - - |
- - |
-8.18% 584/804 |
0.78% 468/850 |
5.02% 759/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 景顺长城中证500指数增强A VS. 长安沪深300非周期A(740101) |